Biblio

Export 2680 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Keyword is A  [Clear All Filters]
2022
A. M. Wessels, Belger, M., Johnston, J. A., Yu, Y., Rentz, D. M., Dowsett, S. A., and Chandler, J., “Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.”, J Alzheimers Dis, vol. 88, no. 2, pp. 577-588, 2022.
Z. Liu, Paek, E. Jin, Yoon, S. On, Casenhiser, D., Zhou, W., and Zhao, X., “Detecting Alzheimer's Disease Using Natural Language Processing of Referential Communication Task Transcripts.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1385-1398, 2022.
Z. Liu, Paek, E. Jin, Yoon, S. On, Casenhiser, D., Zhou, W., and Zhao, X., “Detecting Alzheimer's Disease Using Natural Language Processing of Referential Communication Task Transcripts.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1385-1398, 2022.
F. Nørregaar Pedersen, Stokholm, L., Pouwer, F., Rubin, K. Hass, Peto, T., Frydkjær-Olsen, U., Thykjær, A. Suhr, Andersen, N., Andresen, J., Bek, T., La Cour, M., Heegaard, S., Højlund, K., Kawasaki, R., Hajari, J. Nouri, Kyvik, K. Ohm, Laugesen, C. Schmidt, Schielke, K. Christina, Simó, R., and Grauslund, J., “Diabetic Retinopathy Predicts Risk of Alzheimer's Disease: A Danish Registry-Based Nationwide Cohort Study.”, J Alzheimers Dis, vol. 86, no. 1, pp. 451-460, 2022.
X. Sun, Suo, X., Xia, X., Yu, C., and Dou, Y., “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
X. Sun, Suo, X., Xia, X., Yu, C., and Dou, Y., “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
X. Sun, Suo, X., Xia, X., Yu, C., and Dou, Y., “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
X. Sun, Suo, X., Xia, X., Yu, C., and Dou, Y., “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
D. Asaoka, Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., Ichimiya, Y., Koido, S., Ohno, K., Bernier, F., Katsumata, N., Nagahara, A., Arai, H., Ohkusa, T., and Sato, N., “Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.”, J Alzheimers Dis, vol. 88, no. 1, pp. 75-95, 2022.
D. Asaoka, Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., Ichimiya, Y., Koido, S., Ohno, K., Bernier, F., Katsumata, N., Nagahara, A., Arai, H., Ohkusa, T., and Sato, N., “Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.”, J Alzheimers Dis, vol. 88, no. 1, pp. 75-95, 2022.
D. Asaoka, Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., Ichimiya, Y., Koido, S., Ohno, K., Bernier, F., Katsumata, N., Nagahara, A., Arai, H., Ohkusa, T., and Sato, N., “Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.”, J Alzheimers Dis, vol. 88, no. 1, pp. 75-95, 2022.
F. Fan, Liu, H., Shi, X., Ai, Y., Liu, Q., and Cheng, Y., “The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1195-1204, 2022.
F. Fan, Liu, H., Shi, X., Ai, Y., Liu, Q., and Cheng, Y., “The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1195-1204, 2022.
F. Fan, Liu, H., Shi, X., Ai, Y., Liu, Q., and Cheng, Y., “The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1195-1204, 2022.
D. Cutuli, Landolfo, E., Petrosini, L., and Gelfo, F., “Environmental Enrichment Effects on the Brain-Derived Neurotrophic Factor Expression in Healthy Condition, Alzheimer's Disease, and Other Neurodegenerative Disorders.”, J Alzheimers Dis, vol. 85, no. 3, pp. 975-992, 2022.
D. Cutuli, Landolfo, E., Petrosini, L., and Gelfo, F., “Environmental Enrichment Effects on the Brain-Derived Neurotrophic Factor Expression in Healthy Condition, Alzheimer's Disease, and Other Neurodegenerative Disorders.”, J Alzheimers Dis, vol. 85, no. 3, pp. 975-992, 2022.
X. Wang, Li, F., Gao, Q., Jiang, Z., Abudusaimaiti, X., Yao, J., and Zhu, H., “Evaluation of the Accuracy of Cognitive Screening Tests in Detecting Dementia Associated with Alzheimer's Disease: A Hierarchical Bayesian Latent Class Meta-Analysis.”, J Alzheimers Dis, vol. 87, no. 1, pp. 285-304, 2022.
S. Tok, Ahnaou, A., and Drinkenburg, W., “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
S. Tok, Ahnaou, A., and Drinkenburg, W., “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
S. Tok, Ahnaou, A., and Drinkenburg, W., “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
L. Clare, Martyr, A., Gamble, L. D., Pentecost, C., Collins, R., Dawson, E., Hunt, A., Parker, S., Allan, L., Burns, A., Hillman, A., Litherland, R., Quinn, C., Matthews, F. E., and Victor, C., “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
L. Clare, Martyr, A., Gamble, L. D., Pentecost, C., Collins, R., Dawson, E., Hunt, A., Parker, S., Allan, L., Burns, A., Hillman, A., Litherland, R., Quinn, C., Matthews, F. E., and Victor, C., “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
L. Clare, Martyr, A., Gamble, L. D., Pentecost, C., Collins, R., Dawson, E., Hunt, A., Parker, S., Allan, L., Burns, A., Hillman, A., Litherland, R., Quinn, C., Matthews, F. E., and Victor, C., “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
L. Clare, Martyr, A., Gamble, L. D., Pentecost, C., Collins, R., Dawson, E., Hunt, A., Parker, S., Allan, L., Burns, A., Hillman, A., Litherland, R., Quinn, C., Matthews, F. E., and Victor, C., “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
B. Teichmann, Gkioka, M., Kruse, A., and Tsolaki, M., “Informal Caregivers' Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 971-984, 2022.

Pages